Quantification of Phosphorylated Alpha-synuclein in Cutaneous Biopsies as a Prospective Biomarker in Parkinson's Disease

Launched by CND LIFE SCIENCES · Sep 28, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a substance called phosphorylated alpha-synuclein (P-SYN) to see how it relates to Parkinson's disease and REM Behavior Disorder. Researchers will take small skin samples, known as punch biopsies, from participants to measure the levels of P-SYN. The goal is to understand how P-SYN changes over time and whether it can be used as a marker to track the progression of these conditions.

To participate, individuals must be between 50 and 100 years old and have a confirmed diagnosis of either Parkinson's disease or REM Sleep Behavior Disorder. Participants can expect to undergo a simple skin biopsy, which is a minor procedure done under local anesthesia. However, some people may not be eligible if they have certain health issues, such as severe vascular disease or a history of allergic reactions to the anesthetic. This study is currently recruiting participants, and it's a great opportunity to contribute to research that could lead to better understanding and treatment options for these conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Male and female 50 to 100 years of age
• • 2. Clinical confirmed diagnosis of Parkinson\'s disease or REM Sleep Behavior
• Exclusion Criteria:
• • 1. Clinical evidence of severe vascular disease (history of ulceration, poor wound healing or vascular claudication)
• • 2. History of allergic reaction to Lidocaine for local anesthesia needed for skin biopsies
• • 3. Use of blood thinners (Plavix or Aspirin used separately is allowed)
• • 4. Significantly impaired wound healing or history of scarring or keloid formation